| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1251 | 2018 |
| Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional … DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ... Journal of Clinical Oncology 37 (18), 1558, 2019 | 1016 | 2019 |
| Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing J Zhang, J Fujimoto, J Zhang, DC Wedge, X Song, J Zhang, S Seth, ... Science 346 (6206), 256-259, 2014 | 1015 | 2014 |
| Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic … DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ... The lancet oncology 17 (12), 1672-1682, 2016 | 1009 | 2016 |
| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 781 | 2015 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 436 | 2021 |
| Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC X Le, S Puri, MV Negrao, MB Nilsson, J Robichaux, T Boyle, JK Hicks, ... Clinical Cancer Research 24 (24), 6195-6203, 2018 | 341 | 2018 |
| MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data Y Fan, L Xi, DST Hughes, J Zhang, J Zhang, PA Futreal, DA Wheeler, ... Genome biology 17, 1-11, 2016 | 273 | 2016 |
| Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases GM Fischer, A Jalali, DA Kircher, WC Lee, JL McQuade, LE Haydu, ... Cancer discovery 9 (5), 628-645, 2019 | 261 | 2019 |
| Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer CA Stewart, CM Gay, Y Xi, S Sivajothi, V Sivakamasundari, J Fujimoto, ... Nature cancer 1 (4), 423-436, 2020 | 258 | 2020 |
| Structure-based classification predicts drug response in EGFR-mutant NSCLC JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ... Nature 597 (7878), 732-737, 2021 | 235 | 2021 |
| Caspase-dependent and-independent activation of acid sphingomyelinase signaling JA Rotolo, J Zhang, M Donepudi, H Lee, Z Fuks, R Kolesnick Journal of Biological Chemistry 280 (28), 26425-26434, 2005 | 210 | 2005 |
| Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer G Schvartsman, SA Peng, G Bis, JJ Lee, MFK Benveniste, J Zhang, ... Lung Cancer 112, 90-95, 2017 | 203 | 2017 |
| Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. T Cascone, WN William, A Weissferdt, HY Lin, CH Leung, BW Carter, ... Journal of Clinical Oncology 37 (15_suppl), 8504-8504, 2019 | 202 | 2019 |
| Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ... Journal of Thoracic Oncology 17 (3), 399-410, 2022 | 185 | 2022 |
| TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ... Cancer discovery 7 (10), 1088-1097, 2017 | 178 | 2017 |
| ATM regulates target switching to escalating doses of radiation in the intestines HJ Ch'ang, JG Maj, F Paris, HR Xing, J Zhang, JP Truman, ... Nature medicine 11 (5), 484-490, 2005 | 169 | 2005 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 168 | 2020 |
| Genomic heterogeneity of multiple synchronous lung cancer Y Liu, J Zhang, L Li, G Yin, J Zhang, S Zheng, H Cheung, N Wu, N Lu, ... Nature communications 7 (1), 13200, 2016 | 156 | 2016 |
| Relationship between tumor size and survival in non–small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry J Zhang, KA Gold, HY Lin, SG Swisher, Y Xing, JJ Lee, ES Kim, ... Journal of Thoracic Oncology 10 (4), 682-690, 2015 | 156 | 2015 |
John HeymachChair, Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer CenterPotvrđena adresa e-pošte na mdanderson.org
